Copyright © 2001 by the European Society of Cardiology.
Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat?
a Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands
b Thoraxcenter, Department of Cardiology, Erasmus University, Rotterdam, The Netherlands
revised June 26, 2000; accepted June 28, 2000
Abstract
Aims Treatment guidelines have been developed for both ‘primary’ and ‘secondary’ prevention of coronary heart disease. These should consider both the efficacy as well as the costs of such treatment, particularly the costs of treatment with HMG co-enzyme A reductase inhibitors (statins). In the context of guideline development in The Netherlands, the cost effectiveness of treatment with statins was analysed.
Methods Following a modelling approach, cost effectiveness was analysed as a function of a patient's initial risk for new coronary heart disease events, combining results from 4S, CARE, LIPID, WOSCOPS and AFCAPS with Dutch cost data. For each sex and age group, an estimate was made of the level of cardiovascular risks that might correspond to a cost-effectiveness ratio under NLG 40000 (Euro 18151) per life year gained.
Results If the 10-year risk of myocardial infarction, stroke or cardiovascular death was estimated at 9% (AFCAPS/TexCAPS), 20% (WOSCOPS), 36% (CARE) 36% (LIPID) and 47% (4S), cost effectiveness was estimated at Euro 51400, Euro 26013, Euro 9970, Euro 8028 and Euro 6695. The arbitrary threshold of NLG 40000 (approximately Euro 18000) was achieved at a 10 year coronary heart disease event risk ranging from 19% to 26% for different age groups. Assuming the effectiveness of statin treatment decreased with age, a 10-year risk, corresponding to Euro 18000, varied from 11% (under age 30) to 41% (over age 80). Patients at higher risk levels should be considered for statin therapy.
Conclusions Treatment costs for primary or secondary prevention are determined predominantly by the costs of statin drugs. The developed model allows comparison of cost effectiveness of statin therapy across a wide range of subjects with or without coronary heart disease. The consensus committee in the Netherlands postulated that drug therapy should be considered in subjects with or without coronary heart disease in which cost-effectiveness is similar. Such groups can be identified using the presented model. When cost effectiveness ratios up to Euro 18000 per life year gained are deemed acceptable, statin treatment should be considered in most patients with known cardiovascular disease (secondary prevention), and in a limited group of subjects who are at high risk of developing coronary heart disease (primary prevention).
Key Words: HMG coenzyme reductase inhibitors, cost effectiveness, treatment guidelines
References
- Castelli WP, Garrison RJ, Wilson PW. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA. 1986;256:2835–2838
[Abstract/Free Full Text] - Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA. 1987;257:2176–2180
[Abstract/Free Full Text] - Lancet. 1994;344:
- Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
[Abstract/Free Full Text] - Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
[Abstract/Free Full Text] - Downs, JR, Clearfield, M, Weis, S, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels, JAMA, 1998, 279, 1615, 22
- N Engl J Med. 1998;339:1349–1357
[Abstract/Free Full Text] - Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332–336
[Abstract/Free Full Text] - Caro J, Klittich W, McGuire A, Ford I. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Br Med J. 1997;315:1577–1582
[Abstract/Free Full Text] - Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 1996;17:1001–1007
[Abstract/Free Full Text] - Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Economics. 1997;6:589–601[CrossRef][Web of Science][Medline]
- Ashraf T, Hay JW, Pitt B. Cost effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996;78:409–414[CrossRef][Web of Science][Medline]
- Hay JW, Yu MW, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics. 1999;15:47–74[CrossRef][Web of Science][Medline]
- Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. Br Med J. 1996;312:
- Thorvik E, Aursnes I, Kristiansen IS, Waaler HT. Cost-effectiveness of cholesterol-lowering drugs: A review of the evidence. Wien Klin Wochenschr. 1996;108/8:234–243
- Pedersen TR, Kjekshus J. Cholesterol lowering and the use of healthcare resources:results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:
- Van Hout BA, Goes ES, Grijseels EWM, Quarles van Ufford MA. Economic evaluation in the field of cardiology: theory and practice. Progr Cardiovasc Dis. 1999;42:167–173[CrossRef][Web of Science][Medline]
- Jukema JW, Bruschke AVG, Reiber JHC. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The REgression GRowth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528–2540
[Abstract/Free Full Text] - Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 1994;308:367–373
[Abstract/Free Full Text] - MAAS investigators, Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS), Lancet, 1994, 344, 633, 8, Lancet, 1994, 344, 762
- Pitt B, Mancini J, Ellis SG. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133–1139[Abstract]
- Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, Knook DL, Meinders AE. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119–1123[CrossRef][Web of Science][Medline]
- Vos J, de Feyter PJ, Simoons ML, Tijssen JGP, Deckers JW. Retardation and arrest of progression or regression of coronary artery disease: a review. Progr Cardiovasc Dis. 1993;35:435–454[CrossRef][Web of Science][Medline]
- Uusitupa MIJ, Niskanen LK, Siitonen O. Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type II diabetic and nondiabetic subjects. Diabetologia. 1993;36:1175–1184[CrossRef][Web of Science][Medline]
- Ruygrok PN, de Jaegere PP, van Domburg RT, van den Brand MJ, Serruys PW, de Feyter PJ. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients. J Am Coll Cardiol. 1996;27:1669–1677[Abstract]
- Serruys, PW, The ARTS study
- Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. N Engl J Med. 1997;337:1052–1057
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Nexoe, P. A. Halvorsen, and I. S. Kristiansen Review Article: Critiques of the risk concept -- valid or not? Scand J Public Health, December 1, 2007; 35(6): 648 - 654. [Abstract] [PDF]
|
|
|
|
 |
|
 P. A. Halvorsen, R. Selmer, and I. S. Kristiansen Different Ways to Describe the Benefits of Risk-Reducing Treatments: A Randomized Trial Ann Intern Med, June 19, 2007; 146(12): 848 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H Franco, E. W Steyerberg, A. Peeters, and L. Bonneux Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention. J Epidemiol Community Health, October 1, 2006; 60(10): 839 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. H Franco, E. W Steyerberg, and C. de Laet The polypill: at what price would it become cost effective? J Epidemiol Community Health, March 1, 2006; 60(3): 213 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. H Franco, A. Peeters, C. W N Looman, and L. Bonneux Cost effectiveness of statins in coronary heart disease J Epidemiol Community Health, November 1, 2005; 59(11): 927 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.T. Ong The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient QJM, August 1, 2005; 98(8): 599 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Jain, V Wadehra, and A D Timmis Management of stable angina Postgrad. Med. J., June 1, 2003; 79(932): 332 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Faergeman Estimation and reduction of cardiovascular risk in old people Eur. Heart J., February 2, 2002; 23(4): 261 - 263. [Full Text] [PDF]
|
|
|
|
|
|
R.V. Luepker Cholesterol reduction: What can we afford? Eur. Heart J., May 1, 2001; 22(9): 720 - 721. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||